Amelioration of renal ischemia-reperfusion injury by inhibition of IL-6 production in the poloxamer 407-induced mouse model of hyperlipidemia

Journal of Pharmacological Sciences

Volumn 110, Issue 1, 2009, Pages 47-54

  Sharyo, Satoru ^a,b   Kumagai, Kazuyoshi ^b   Yokota Ikeda, Naoko ^c   Ito, Katsuaki ^a   Ikeda, Masahiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

Author keywords

Angiopoietin like 3 deficient mouse; Apolipoprotein E knockout mouse; IL 6; Poloxamer 407; Renal ischemia reperfusion injury

Indexed keywords

INTERLEUKIN 6; POLOXAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MODEL; HYPERLIPIDEMIA; KIDNEY ISCHEMIA; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; REPERFUSION INJURY; SPLEEN CELL;

EID: 66349112357     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08283FP     Document Type: Article

References (32)

1. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 2006;17:1143-1150.
2. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17:1503-1520. (Pubitemid 43841396)
3. Ikeda M, Prachasilchai W, Burne-Taney MJ, Rabb H, Yokota-Ikeda N. Ischemic acute tubular necrosis models and drug discovery: a focus on cellular inflammation. Drug Discov Today. 2006;11:364-370.
4. Patel NS, Chatterjee PK, Di Paola R, Mazzon E, Britti D, De Sarro A, et al. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther. 2005;312:1170-1178. (Pubitemid 40293778)
5. Kielar ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, et al. Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol. 2005;16:3315-3325. (Pubitemid 46179335)
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847. (Pubitemid 28213628)
7. Dalrymple LS, Kaysen GA. The Effect of Lipoproteins on the Development and Progression of Renal Disease. Am J Nephrol. 2008;28:723-731.
8. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246-1261. (Pubitemid 46536911)
9. Nitzan M. Abnormalities of carbohydrate and lipid metabolism in experimentally induced acute uremia. Nutr Metab. 1973;15:187-191.
10. -/-) after subtotal nephrectomy. Nephrol Dial Transplant. 2004;19:566-573.
11. Campos SB, Ori M, Dórea EL, Seguro AC. Protective effect of L-arginine on hypercholesterolemia-enhanced renal ischemic injury. Atherosclerosis. 1999;143:327-334. (Pubitemid 29166913)
12. Sharyo S, Yokota-Ikeda N, Mori M, Kumagai K, Uchida K, Ito K, et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int. 2008;74:577-584.
13. Johnston TP, Palmer WK. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J Cardiovasc Pharmacol. 1997;29:580-585. (Pubitemid 27276807)
14. Johnston TP, Baker JC, Jamal AS, Hall D, Emeson EE, Palmer WK. Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice. J Cardiovasc Pharmacol. 1999;34:831-842.
15. Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet. 2002;30:151-157.
16. Fujimoto K, Koishi R, Shimizugawa T, Ando Y. Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim. 2006;55:27-34. (Pubitemid 43349428)
17. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003;170:1517-1523. (Pubitemid 36139523)
18. Zhang Q, Zeng X, Guo J, Wang X. Oxidant stress mechanism of homocysteine potentiating Con A-induced proliferation in murine splenic T lymphocytes. Cardiovasc Res. 2002;53:1035-1042. (Pubitemid 34261042)
19. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-1254.
20. Lai LW, Yong KC, Igarashi S, Lien YH. A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia-reperfusion injury. Kidney Int. 2007;71:1223-1231. (Pubitemid 46884247)
21. Rabb H, Daniels F, O'Donnell M, Haq M, Saba SR, Keane W, et al. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol. 2000;279:F525-F531.
22. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O'Donnell MP, et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest. 2001;108:1283-1290. (Pubitemid 33107755)
23. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430. (Pubitemid 20065229)
24. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000;10:143-148. (Pubitemid 32178190)
25. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007;21:1714-1719. (Pubitemid 47076470)
26. Hillyard DZ, Jardine AG, McDonald KJ, Cameron AJ. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis. 2004;172:219-228. (Pubitemid 38167532)
27. Xue X, Lai KT, Huang JF, Gu Y, Karlsson L, Fourie A. Antiinflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib. J Pharmacol Exp Ther. 2006;317:53-60.
28. Kuipers F, van Ree JM, Hofker MH, Wolters H, In't Veld G, Havinga R, et al. Altered lipid metabolism in apolipoprotein E-deficient mice dose not affect cholesterol balance across the liver. Hepatology. 1996;24:241-247.
29. Moghadasian MH, McManus BM, Nguyen LB, Shefer S, Nadji M, Godin DV, et al. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. FASEB J. 2001;15:2623-2630. (Pubitemid 33131089)
30. Scheuer H, Gwinner W, Hohbach J, Gröne EF, Brandes RP, Malle E, et al. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol. 2000;278:F63-F74. (Pubitemid 30106126)
31. Girod WG, Jones SP, Sieber N, Aw TY, Lefer DJ. Effects of hypercholesterolemia on myocardial ischemia-reperfusion injury in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:2776-2781. (Pubitemid 29536057)
32. Jones SP, Girod WG, Marotti KR, Aw TY, Lefer DJ. Acute exposure to a high cholesterol diet attenuates myocardial ischemia-reperfusion injury in cholesteryl ester transfer protein mice. Coron Artery Dis. 2001;12:37-44. (Pubitemid 32108650)